Fujirebio Holdings, Inc. and Eisai Co., Ltd. Establish Non-Exclusive Partnership for Research of Blood-Based Biomarkers in Neurodegenerative Diseases
Fujirebio Holdings, Inc. and Eisai Co., Ltd. Establish Non-Exclusive Partnership for Research of Blood-Based Biomarkers in Neurodegenerative Diseases
12/23/24, 12:05 PM
Location
gentIndustry
mobile
health care
Type
partnership
Fujirebio Holdings, Inc. and Eisai Co., Ltd. have entered into a memorandum of understanding for joint research and social implementation of novel blood-based biomarkers in the field of neurodegenerative diseases, specifically related to Alzheimer’s disease. The partnership aims to integrate their expertise in order to accelerate the development and commercialization of diagnostic methods for neurodegenerative diseases
Company Info
Location
gent, east flanders, belgium
Additional Info
Fujirebio is a global leader in the field of in vitro diagnostics (IVD) testing with more than 50 years’ experience in the conception, development, production and worldwide commercialization of robust IVD products. These span the range from specialized testing to fully automated routine clinical laboratory testing solutions covering a variety of disease states.